


State of AI

ZoomRx surveyed over 200 life sciences professionals to find out the real story about Al in pharma. Read on to learn how pharma is using and building this technology.

Cracking down the use of ChatGPT


More than half of life sciences companies ban their employees from using ChatGPT



65%) of the top 20 pharma


companies do not allow their employees to use ChatGPT

Data security is the primary concern




Company policies seem to be lacking

Only 60% of life sciences companies have provided training or guidelines to their employees on how to use ChatGPT




More employees are using ChatGPT than you think



The many motivations to pursue AI

At the moment, AI is primarily viewed as a tool for cost reduction rather than as a catalyst for business growth and revenue impact






🖵 FERMA.AI A product of ZoomRx

Weighing AI's promise against it's concerns

Despite recognizing its potential, professionals in the pharma sector harbor greater concerns about data security, privacy, and use



AI isn't all that it's hyped up to be


With all the buzz and demoware out there, it's easy to get swept up in the excitement-but respondents were more discerning than blown away



Most companies are still in the early stages of adoption


It's no secret that companies have been jostling to implement Al into their processes, even going so far as to reposition themselves as "Al companies"

However, the majority of companies (58%) have indicated these efforts are in early stages. Further, a non-trivial 8% haven't even started yet



AI use cases run the gamut

From revolutionizing drug discovery to enhancing trial accuracy, Al's transformative impact is reshaping the very DNA of life sciences innovation





For more info, reach us at info@ferma.ai